AIMP1 and pancreatic neoplasm: In pancreatic cancer, EMAP II alone or in combination with bortezomib have anti-proliferative and pro-apoptotic effects, and significantly reduced B-cell lymphoma-2 (Bcl-2) expression (Awasthi et al., 2010).